Canaccord Genuity Downgrades bluebird bio (BLUE) to Hold

Go back to Canaccord Genuity Downgrades bluebird bio (BLUE) to Hold

bluebird bio (BLUE) PT Lowered to $19 at Morgan Stanley

August 11, 2021 8:26 AM EDT

Morgan Stanley analyst Matthew Harrison lowered the price target on bluebird bio (NASDAQ: BLUE) to $19.00 (from $35.00) while maintaining a Equalweight rating.

... More